Type I Interferon Autoantibodies Correlate With Cellular Immune Alterations in Severe COVID-19

J Infect Dis. 2024 Aug 16;230(2):e318-e326. doi: 10.1093/infdis/jiae036.

Abstract

Background: Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can lead to severe disease with increased morbidity and mortality among certain risk groups. The presence of autoantibodies against type I interferons (aIFN-Abs) is one mechanism that contributes to severe coronavirus disease 2019 (COVID-19).

Methods: This study aimed to investigate the presence of aIFN-Abs in relation to the soluble proteome, circulating immune cell numbers, and cellular phenotypes, as well as development of adaptive immunity.

Results: aIFN-Abs were more prevalent in critical compared to severe COVID-19 but largely absent in the other viral and bacterial infections studied here. The antibody and T-cell response to SARS-CoV-2 remained largely unaffected by the presence aIFN-Abs. Similarly, the inflammatory response in COVID-19 was comparable in individuals with and without aIFN-Abs. Instead, presence of aIFN-Abs had an impact on cellular immune system composition and skewing of cellular immune pathways.

Conclusions: Our data suggest that aIFN-Abs do not significantly influence development of adaptive immunity but covary with alterations in immune cell numbers.

Keywords: COVID-19; autoantibodies; immunity; interferon.

MeSH terms

  • Adaptive Immunity / immunology
  • Adult
  • Aged
  • Autoantibodies* / blood
  • Autoantibodies* / immunology
  • COVID-19* / immunology
  • Female
  • Humans
  • Immunity, Cellular
  • Interferon Type I* / immunology
  • Male
  • Middle Aged
  • SARS-CoV-2* / immunology
  • Severity of Illness Index
  • T-Lymphocytes / immunology

Substances

  • Interferon Type I
  • Autoantibodies